中國生物科技服務(08037.HK)與港深創新及科技園簽署諒解備忘錄
格隆匯4月18日丨中國生物科技服務(08037.HK)公吿,港深創新及科技園有限公司("港深創科園公司")與大約60個合作伙伴機構(包括公司)簽署諒解備忘錄後,已於2024年4月18日舉行港深創科園合作伙伴啟動禮。根據公司與港深創科園公司(統稱為"有關各方")所訂立諒解備忘錄,有關各方已經協定(其中包括)合作開發位於河套深港科技創新合作區落馬洲河套地區港深創新及科技園。
發展硼中子俘獲治療癌症治療中心及提供腫瘤免疫細胞治療服務為集團其中主要業務活動。諒解備忘錄標誌着公司將會在創科園設立香港首個硼中子俘獲治療中心,在未來服務香港、大灣區、東南亞及南亞地區的晚期癌症患者。有關硼中子俘獲治療設備及相關服務將會由Sumitomo Heavy Industries,Ltd.("住友")及Stella Pharma Corporation("Stella Pharma")根據彼等各自先前與集團訂立協議提供。公司亦承認,住友及Stella Pharma各自均已經與港深創科園公司簽署諒解備忘錄。
董事會相信,由於建立包含本集團分子診斷實驗室、CAR-T開發中心及硼中子俘獲治療中心綜合中心,與港深創科園公司合作會產生協同效應。有關綜合中心將便利在香港生產首個以CD20為靶點的自體CAR-T治療藥物及開發硼中子俘獲治療。董事會進一步相信,訂立諒解備忘錄與政府推動將香港發展成為區域科學研究中心及促進內地與香港合作政策相符。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.